Αποτελέσματα Αναζήτησης
18 Σεπ 2024 · Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome in which patients have signs and symptoms of HF as the result of high left ventricular (LV) filling pressure despite normal or near normal LV ejection fraction (LVEF; ≥50 percent) [1-5].
- Wilson S Colucci, MD
Wilson S Colucci, MD - Treatment and prognosis of heart...
- Cleland Jgf, Bunting Kv, Flather Md, Et Al. Beta-blockers for Heart Failure With Reduced, Mid-Range, and Preserved Ejection Fraction: an Individual Patient-Level Analysis of Double-Blind Randomized Trials. Eur Heart J 2018; 39:26
Medline ® Abstract for Reference 31 of 'Treatment and...
- Schwartzenberg S, Redfield Mm, From Am, Et Al. Effects of Vasodilation in Heart Failure With Preserved Or Reduced Ejection Fraction Implications of Distinct Pathophysiologies on Response to Therapy. J Am Coll Cardiol 2012; 59:442
UpToDate, electronic clinical resource tool for physicians...
- Liao L, Jollis Jg, Anstrom Kj, Et Al. Costs for Heart Failure With Normal vs Reduced Ejection Fraction. Arch Intern Med 2006; 166:112
UpToDate, electronic clinical resource tool for physicians...
- Persson H, Lonn E, Edner M, Et Al. Diastolic Dysfunction in Heart Failure With Preserved Systolic Function: Need for Objective Evidence:Results From The Charm Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 2007; 49:687
BACKGROUND The mode of death has been well characterized in...
- Yancy Cw, Jessup M, Bozkurt B, Et Al. 2013 Accf/Aha Guideline for The Management of Heart Failure: a Report of The American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:E147
These therapies have not been proven to be effective in...
- Ahmed A, Rich Mw, Fleg Jl, Et Al. Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial. Circulation 2006; 114:397
Medline ® Abstract for Reference 36 of 'Treatment and...
- Hasenfuß G, Hayward C, Burkhoff D, Et Al. a Transcatheter Intracardiac Shunt Device for Heart Failure With Preserved Ejection Fraction (Reduce Lap-Hf): a Multicentre, Open-Label, Single-Arm, Phase 1 Trial. Lancet 2016; 387:1298
METHODS The REDUCe Elevated Left Atrial Pressure in Patients...
- Wilson S Colucci, MD
13 Ιουλ 2021 · Treatment overview — Clinical trials of pharmacologic therapy for HFpEF have produced largely neutral results. Thus, the management of patients with HFpEF is mostly directed toward treating associated conditions (eg, hypertension, atrial fibrillation [AF]) and symptoms (eg, edema).
Chronic kidney disease — Patients with HFpEF and CKD should be treated with best-practices for CKD, which include treatments that reduce the progression of CKD (eg, renin-angiotensin-aldosterone system [RAAS] inhibition and SGLT2 inhibitor therapy).
19 Μαρ 2024 · Heart Failure with Preserved Ejection Fraction (HFpEF): patients with an LVEF ≥50% with evidence of spontaneous or provokable increased left ventricular filling pressures (LVFPs), characterized by elevated natriuretic peptides or hemodynamic measurements.
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome in patients with current or prior symptoms of HF with a left ventricular ejection fraction (LVEF) ≥50 percent and evidence of cardiac dysfunction as the cause of symptoms (eg, abnormal LV filling pattern and elevated filling pressures) [1-5].
Heart failure (HF) can be defined as the inability of the heart to provide sufficient forward output to meet the perfusion and oxygenation requirements of the tissues while maintaining normal filling pressures. There are two major cardiac mechanisms by which this can occur.
Clinicians should: 1) perform testing, as guided by the history and physical examination, to exclude cardiac and noncardiac HF mimics and identify comorbidities in individuals with dyspnea and/or edema, and preserved EF; and 2) implement an HFpEF treatment plan with specific attention to the management of comorbidities and the role of ...
